Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

50.6K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inflammatory, Cardiac, and Lipid-Related Biomarkers in Relation to Residual MACE Risk in the REPRIEVE Trial.

JACC. Advances·2026
Same author

Pitavastatin effect on enterocyte injury markers in an ART treated HIV population: Insights from REPRIEVE.

AIDS (London, England)·2026
Same author

Semaglutide improves markers of cardiovascular risk in people with HIV.

AIDS (London, England)·2026
Same author

Incidence, risk factors, and cardiovascular impact of hypertension in people with HIV: a secondary analysis of the REPRIEVE trial.

The lancet. HIV·2026
Same author

Prospective HIV RNA screening with long-acting cabotegravir pre-exposure prophylaxis in HPTN 083.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysis.

The lancet. HIV·2026

Related Experiment Video

Updated: Mar 29, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.5K

HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial.

Karen T Tashima, Laura M Smeaton, Carl J Fichtenbaum

    Annals of Internal Medicine
    |November 24, 2015
    PubMed
    Summary

    Omitting nucleoside reverse transcriptase inhibitors (NRTIs) in experienced HIV patients on optimized regimens is safe and effective. This approach reduces pill burden, cost, and toxicity without compromising virologic outcomes.

    More Related Videos

    Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
    06:07

    Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

    Published on: October 6, 2022

    3.0K
    Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
    07:10

    Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

    Published on: January 7, 2019

    16.5K

    Related Experiment Videos

    Last Updated: Mar 29, 2026

    Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
    05:46

    Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

    Published on: April 9, 2014

    18.5K
    Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
    06:07

    Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

    Published on: October 6, 2022

    3.0K
    Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
    07:10

    Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

    Published on: January 7, 2019

    16.5K

    Area of Science:

    • Infectious Diseases
    • Virology
    • Clinical Pharmacology

    Background:

    • Nucleoside reverse transcriptase inhibitors (NRTIs) are commonly used in antiretroviral therapy for treatment-experienced HIV patients, despite limited trial data.
    • Optimized antiretroviral regimens often include NRTIs, but their necessity in all cases is not well-established.

    Purpose of the Study:

    • To compare treatment success in HIV patients who omit versus add NRTIs to an optimized antiretroviral regimen.
    • To evaluate the safety and efficacy of NRTI omission in treatment-experienced individuals with viral resistance.

    Main Methods:

    • A multicenter, randomized, controlled trial involving treatment-experienced HIV patients with viral resistance.
    • Participants received an optimized regimen and were randomized to either omit or add NRTIs.
    • Primary outcomes included regimen failure at 48 weeks and safety endpoints.

    Main Results:

    • No significant difference in regimen failure rates between the omit-NRTI (29.8%) and add-NRTI (25.9%) groups.
    • Similar virologic efficacy (HIV RNA <50 copies/mL) and safety profiles were observed between groups.
    • The omit-NRTI group experienced no deaths, compared to 7 deaths in the add-NRTI group.

    Conclusions:

    • Treatment-experienced HIV patients initiating a new optimized regimen can safely omit NRTIs.
    • NRTI omission does not compromise virologic efficacy and offers benefits like reduced pill burden, cost, and toxicity.
    • The unblinded design may limit applicability in resource-poor settings.